Connect with us

Business

Dr. Nalinda Jayatissa visits LAUGFS Life Sciences’ State-of-the-Art (LVP) pharmaceutical facility

Published

on

The Minister of Health and Mass Media, Dr. Nalinda Jayatissa, undertook an observational visit to the state-of-the-art sterile pharmaceutical manufacturing facility of LAUGFS Life Sciences (Pvt) Ltd, located within the BOI Export Processing Zone, Koggala. This visit reflects the company’s commitment to strengthening Sri Lanka’s healthcare system through world-class local manufacturing. Marking a significant milestone for the country’s healthcare industry, LAUGFS Life Sciences is advancing sterile infusion therapy production, reducing reliance on imports, delivering economic and clinical benefits, and positioning Sri Lanka as a regional hub for quality-driven pharmaceutical manufacturing through innovation, regulatory compliance, and private-sector investment.

The Minister was warmly welcomed by Dr. Ravi Edirisinghe, Group Chief Executive Officer of LAUGFS Holdings Limited, Dr. Rajiv Perera, Chief Executive Officer of LAUGFS Life Sciences (Pvt) Ltd., Vipin Kumar Head of Quality, Ranjith Reddy, General Manager – Operations, and Wasaam Ismail, General Manager – Head of Corporate Communications, along with senior managers, quality specialists, and engineers of the facility.

During the visit, the Minister observed LAUGFS Life Sciences’ advanced sterile infusion production lines. The company is preparing to introduce Large Volume Parenterals (LVPs) using Euro Multiport systems and Form-Fill-Seal (FFS) technology. Euro Multiport ensures high-safety, multi-access containers for clinical use, while FFS automates forming, filling, and sealing in a sterile environment, minimising human intervention and contamination risks. These innovations aim to transform infusion therapy in Sri Lanka by reducing import dependence, ensuring steady supply, and offering affordable solutions for both public and private healthcare sectors.

Commending the initiative, the Minister of Health and Mass Media, Dr. Nalinda Jayatissa, stated, “This project is a commendable step forward for Sri Lanka’s healthcare sector. By investing in advanced pharmaceutical manufacturing, LAUGFS Life Sciences directly supports the Government’s vision of enhancing local production, saving valuable foreign exchange, and providing our citizens with reliable, world-class medical solutions. Public-private partnerships of this nature are critical to building a resilient healthcare system and ensuring patient safety and continuity of treatment.”

Commenting on this significant occasion, Dr. Ravi Edirisinghe, Group Chief Executive Officer of LAUGFS Holdings Limited, remarked, “At LAUGFS, we believe in creating industries that bring long-term value to Sri Lanka. Through LAUGFS Life Sciences, we are making strategic investments in sterile pharmaceutical technologies that will not only benefit the local healthcare sector but also strengthen our position as a regional hub for pharmaceutical manufacturing.”

Adding his perspective, Dr. Rajiv Perera, Chief Executive Officer of LAUGFS Life Sciences, commented, “We are committed to ensuring that Sri Lanka has access to globally benchmarked infusion therapies through our advanced LVP production lines. With the integration of Euro Multiport and Form-Fill-Seal technologies, we are setting new standards in quality, safety, and efficiency that will directly benefit both patients and healthcare providers.”

LAUGFS Life Sciences specialises in manufacturing Large Volume Parenteral (LVP) IV solutions to meet critical healthcare needs across local and regional markets. Operating a state-of-the-art facility at the BOI Export Processing Zone, Koggala, it utilises advanced production technologies and adheres to cGMP guidelines set by WHO, NMRA, and other global regulatory authorities to ensure stringent quality assurance. With a portfolio of 20+ IV fluid products, including electrolytes, dextrose solutions, and critical care medications, LAUGFS Life Sciences manufactures in high-quality Non-PVC polypropylene (PP) bags using Form Fill-Seal (FFS) & Eurocap technology, supported by a fully automated production process that guarantees maximum efficiency, product integrity, and consistency.



Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Constituent Change in the S&P Sri Lanka 20 Index

Published

on

The Colombo Stock Exchange (CSE) announces the following change in S&P Sri Lanka 20 index constituents made by S&P Dow Jones Indices at the 2026 Mid-Year rebalance.

The exclusion and inclusion as announced by S&P Dow Jones Indices, effective from 22nd June 2026 (after the market close of 19th June 2026) are presented below.

The S&P SL 20 index includes the 20 largest companies, by total market capitalization, listed on the CSE that meet minimum size, liquidity and financial viability thresholds. The constituents are weighted by float-adjusted market capitalization, subject to a single stock cap of 15%, which is employed to reduce single stock concentration.

The S&P SL 20 index has been designed in accordance with international practices and standards. All stocks are classified according to the Global Industry Classification Standard (GICS®), which was co-developed by S&P Dow Jones Indices and MCSI and is widely used by market participants throughout the world.

To be eligible for inclusion, a stock must have a minimum float-adjusted market capitalization of 500 million Sri Lankan rupees (Rs), a six-month median daily value traded of Rs 0.25 million and have positive net income over the 12 months prior to the rebalancing reference date. For information, including the complete methodology, please visit: www.spindices.com

Effective from 22nd June 2026 the stocks in the S&P Sri Lanka 20 in alphabetical order are as above.

Continue Reading

Business

Teejay Group navigates industry headwinds with financial strength and strategic focus

Published

on

Teejay Lanka Chairman Ajit Gunewardene and CEO Pubudu De Silva

The Teejay Group recorded revenue of LKR 60.04 billion during the period, reflecting a 10% year-on-year decline, primarily due to continued softness in global textile demand. This performance was largely impacted by reciprocal tariffs imposed by the United States, intensified pricing pressures across key markets, and the resulting decline in volumes, all of which collectively weighed on topline growth.

Group Gross Profit declined by 36% year-on-year to LKR 5.02 billion, mainly attributable to lower production volumes, underutilization of plant capacity, sustained pricing pressures, and an unfavorable product mix. Together, these factors adversely affected margin performance amid a challenging operating environment.

The Group reported a Profit After Tax (PAT) of LKR 54.7 million, representing a 98% year-on-year decline. This was primarily driven by higher rupee-denominated costs and non-recurring items, provision for doubtful debts, and restructuring costs associated with right-sizing initiatives.

Ajit Gunewardene, Chairman of the Teejay Group said, “The year was marked by persistent global demand softness and pricing pressures, which impacted results. Despite this, we focused on operational efficiency, cost discipline, and strengthening our financial resilience. These actions position the Group to navigate ongoing uncertainty while remaining committed to long-term value creation for our shareholders.”

Despite these near-term challenges, the Teejay Group continues to maintain a strong financial position, supported by disciplined working capital management and a robust liquidity base. As at 31 March 2026, cash and cash equivalents stood at LKR 8.3 billion, while the Group’s net asset base increased by 3% year-on-year to LKR 32.4 billion, reinforcing the resilience of its balance sheet.

Continue Reading

Business

Fairfirst celebrates 7 years of supporting the Sri Lanka Police K9 Unit

Published

on

Fairfirst Insurance has once again partnered with the Sri Lanka Police K9 Unit, continuing its support for the seventh consecutive year. This partnership reflects the company’s long-standing commitment to giving back to the community.

Through this initiative, Fairfirst will provide comprehensive insurance coverage for the highly trained canines attached to the Sri Lanka Police K9 Unit. These dogs play a critical role in supporting police operations across the country, assisting with crime detection, narcotics investigations, search and rescue missions, and public safety efforts.

As a company that believes business should create a meaningful impact beyond insurance, Fairfirst remains committed to initiatives that support communities and recognise the vital contributions of those who help keep society safe. This shared commitment to protection and responsibility continues to drive the company’s long-standing partnership with the Sri Lanka Police K9 Unit.

Commenting on the continued partnership, Ravishankar Wickneswaran, CEO of Fairfirst Insurance, said, “It is a privilege for us to continue supporting the Sri Lanka Police K9 Unit for the seventh consecutive year. These dogs serve the country with incredible discipline and loyalty, often in challenging situations. Supporting their wellbeing is one small way for us to give back, and it reflects the FairfirstWay of standing by those who protect and serve our communities every day.”

Fairfirst looks forward to continuing this partnership and contributing to the wellbeing of the Sri Lanka Police K9 Unit in the years ahead.

Continue Reading

Trending